|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
EBSCO_ocn991595824 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
170626s2017 nyu ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d EBLCP
|d OCLCF
|d YDX
|d AGLDB
|d IGB
|d AUW
|d BTN
|d MHW
|d INTCL
|d SNK
|d A6Q
|d G3B
|d S8I
|d S8J
|d S9I
|d STF
|d D6H
|d M8D
|d OCLCQ
|d K6U
|d OCLCQ
|d OCLCO
|d OCLCQ
|
| 066 |
|
|
|c (S
|
| 020 |
|
|
|a 9781536121353
|q (electronic bk.)
|
| 020 |
|
|
|a 1536121355
|q (electronic bk.)
|
| 020 |
|
|
|z 9781536121193
|
| 035 |
|
|
|a (OCoLC)991595824
|
| 050 |
|
4 |
|a RC667
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.12
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Cardiotoxicity of chemotherapeutic agents /
|c Gregg M. Lanier, Jalaj Garg and Neeraj Shah, editors.
|
| 264 |
|
1 |
|a New York :
|b Nova Science Publishers,
|c 2017.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed June 27, 2017)
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Preface; Chapter 1; Introduction: Cardiotoxicity of Chemotherapeutic Agents; Introduction; References; Chapter 2; Alkylating Agents; Cyclophosphamide; Ifosphamide (IFS); Carboplatin; Busulfan; Altretamine (Hexalen); Procarbazine; References; Chapter 3; Antimetabolites; 5-Fluorouracil; Raltitrexed (Tomudex); Cytosine Arabinoside (Cytarabine or Ara-C); Gemcitabine; Pentostatin; Other Antimetabolites; References; Chapter 4; Antitumor Antibiotics: Bleomycin and Mitoxantrone; Bleomycin; Mitoxantrone; References; Chapter 5
|
| 505 |
8 |
|
|a I. Electrocardiogram (EGC) Changes and Arrhythmias Associated with Anthracycline Useii. Chronic Cardiomyopathy; iii. Sub-Clinical Cardiotoxicity; Risk Factors Associated with Poor Long-Term Cardiovascular Outcomes; References; Chapter 7; Antitumor Antibiotics: Anthracyclines and Minimizing Cardiotoxicity; Approaches to Minimize Anthracycline Cardiotoxicity; 1. Pharmacokinetic Approaches for Cardiac Prevention; 2. Pharmacogenetic Approaches for Cardiac Prevention; 3. Chemo Protectants and Adjunctive Therapies to Reduce Cardiotoxicity; References; Chapter 8
|
| 505 |
8 |
|
|a Antitumor Antibiotics: Newer AnthracyclinesNew Anthracyclines; References; Chapter 9; Microtubule Inhibitors; Microtubule Inhibitors; Paclitaxel; Docetaxel; Vinca Alkaloids; Eribulin; Ixabepilone; References; Chapter 10; Hormonal Therapy; Estrogens; Aromatase Inhibitors; Progestins; Tamoxifen; Androgen Deprivation Therapy; Flutamide; Leuprolide; Cyproterone Acetate; References; Chapter 11; Immunotherapy; Interleukin; Interferon; References; Chapter 12; Monoclonal Antibodies; Trastuzumab; Rituximab; Alemtuzumab; Bevacizumab; Cetuximab; Gemtuzumab; Ibritumomab; Tositumomab; References
|
| 505 |
8 |
|
|a Chapter 13Tyrosine Kinase Inhibitors; Imatinib; Dasatinib; Nilotinib; Sunitinib; Sorafenib; Lapatinib; Erlotinib and Geftinib; Other Tyrosine Kinase Inhibitors; References; Chapter 14; Topoisomerase-1 Inhibitors and Miscellaneous Drugs; Topoisomerase-1 Inhibitors; Irinotecan (CAMPTOSAR) and Topotecan (Hycamtin); Other Miscellaneous Drugs; Tretinoin; Arsenic Trioxide (Trisenox); References; About the Editors; Index; Blank Page
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Cardiology.
|
| 650 |
|
0 |
|a Chemotherapy.
|
| 650 |
|
2 |
|a Cardiology
|
| 650 |
|
2 |
|a Drug Therapy
|
| 650 |
|
6 |
|a Cardiologie.
|
| 650 |
|
6 |
|a Chimiothérapie.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Cardiology.
|2 fast
|0 (OCoLC)fst00847121
|
| 650 |
|
7 |
|a Chemotherapy.
|2 fast
|0 (OCoLC)fst00853595
|
| 700 |
1 |
|
|a Lanier, Gregg M.,
|e editor.
|
| 700 |
1 |
|
|a Garg, Jalaj,
|e editor.
|
| 700 |
1 |
|
|a Shah, Neeraj,
|e editor.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1540068
|z Texto completo
|
| 880 |
8 |
|
|6 505-00/(S
|a Antitumor Antibiotics: Anthracyclines, a Mechanism of CardiotoxicityAnthracyclines (Daunorubicin and Doxorubicin); Mechanisms of Anthracycline Toxicity; i. Reactive Oxygen Species and Redox Cycling; ii. Calcium Exchange Channels; iii. Role of GATA4; iv. Changes in Endogenous Adaptive Reserve of the Heart; v. Role of Topoisomerase 2β; vi. Role of Neuregulin-1, ErbB2, and ErbB4 Signalling; References; Chapter 6; Antitumor Antibiotics: Anthracyclines, Cardiotoxicity and Associated Risk Factors; Cardiotoxicity Caused by Anthracyclines
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 14440442
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4882780
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1540068
|
| 994 |
|
|
|a 92
|b IZTAP
|
